medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2019-7-13-20medsovet-2914Research ArticleКЛИНИЧЕСКОЕ НАБЛЮДЕНИЕCLINICAL OBSERVATIONНеоперативное лечение миомы матки. Эффективность использования селективного модулятора прогестероновых рецепторовNon-surgical treatment of uterine fibroids. Efficacy of the selective progesterone receptor modulatorДовлетхановаЭ. Р.DovletkhanovaE. R.

Довлетханова Эльмира Робертовна – к.м.н., старший научный сотрудник научно-поликлинического отделения.

117997, Россия, г. Москва, ул. Академика Опарина, д. 4.

Dovletkhanova Elmira Robertovna – Cand. of Sci. (Med.), Senior Researcher of Research Polyclinic Department.

117997, Russia, Moscow, 4, Oparina str.

e_dovletkhanova@oparina4.ruМежевитиноваЕ. А.MezhevitinovaE. A.

Межевитинова Елена Анатольевна – д.м.н., ведущий научный сотрудник научно-поликлинического отделения.

117997, Россия, г. Москва, ул. Академика Опарина, д. 4.

Mezhevitinova Elena Anatolyevna – Dr. of Sci. (Med.), Senior Researcher of Research Polyclinic Department.

117997, Russia, Moscow, 4, Oparina str.

e_mezhevitinova@oparina4.ruПрилепскаяВ. Н.PrilepskayaV. N.

Prilepskaya Vera Nikolaevna – Dr. of Sci. (Med.), Professor, Deputy Director of Research, Head of Research and Polyclinic Department.

117997, Russia, Moscow, 4, Oparina str.

v_prilepskaya@oparina4.ruФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Министерства здравоохранения Российской Федерации.РоссияFederal State Budgetary Institution “National Medical Research Center of Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov” of the Ministry of Health of the Russian Federation.Russian Federation201902042019071320Copyright © Довлетханова Э.Р., Межевитинова Е.А., Прилепская В.Н., 20192019Довлетханова Э.Р., Межевитинова Е.А., Прилепская В.Н.Dovletkhanova E.R., Mezhevitinova E.A., Prilepskaya V.N.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2914

Ведущая роль стероидных гормонов яичников в патогенезе миомы матки подтверждается рядом эпидемиологических, клинических и экспериментальных исследований. Разработать новые подходы к лечению данного заболевания возможно, опираясь на биологические и генетические механизмы, лежащие в основе возникновения и развития лейомиомы. Применение улипристала ацетата у пациенток с лейомиомой матки является перспективным не только с целью подготовки к операции, но и ввиду возможности избежать хирургического лечения и связанных с ним гипоэстрогенных состояний, в результате улучшая качество жизни женщины.

The leading role of ovarian steroid hormones in the pathogenesis of uterine fibroids is confirmed by epidemiological, clinical and experimental studies. The new approaches to the treatment of this disease may be developed on the basis of the biological and genetic mechanisms underlying the occurrence and development of leiomyomas. The use of ulipristal acetate in patients with uterine leiomyoma may be a promising method for preparing them to the surgical procedures, but also for avoiding surgical treatment and related hypoestrogenic conditions, which results in the improvement of the women’s quality of life.

миома маткистероидные гормоныэстрогенные рецепторыпрогестероновые рецепторыселективные модуляторы прогестеронаулипристала ацетатuterine fibroidssteroid hormonesestrogen receptorsprogesterone receptorsselective progesterone modulatorsulipristal acetateReferencesGao X., Yu L., Moore A.B., et al. Cadmium and proliferation in human uterine leiomyoma cells: evidence of a role for EGFR/MAPK pathways but not classical estrogen receptor pathways. Environ Health Perspect. 2015;123:331-336.Gao X., Yu L., Moore A.B., et al. Cadmium and proliferation in human uterine leiomyoma cells: evidence of a role for EGFR/MAPK pathways but not classical estrogen receptor pathways. Environ Health Perspect. 2015;123:331-336.Islam M.S., Protic O., Giannubilo S.R., et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab. 2013;98:921-934.Islam M.S., Protic O., Giannubilo S.R., et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab. 2013;98:921-934.Plewka D., Marczynski J., Morek M. et al. Receptors of hypothalamic-pituitary-ovarian-axis hormone in uterine myomas. Biomed Res Int. 2014;2014:521313.Plewka D., Marczynski J., Morek M. et al. Receptors of hypothalamic-pituitary-ovarian-axis hormone in uterine myomas. Biomed Res Int. 2014;2014:521313.Wakabayashi А., Takeda T., Tsuiji K., et al. Antiproliferative effect of adiponectin on rat uterine leiomyoma ELT-3 cells. Gynecol Endocrinol. 2011;27:33-38.Wakabayashi А., Takeda T., Tsuiji K., et al. Antiproliferative effect of adiponectin on rat uterine leiomyoma ELT-3 cells. Gynecol Endocrinol. 2011;27:33-38.Islam M.S., Catherino W.H., Protic O., et al. Role of activin-A and myostatin and their signaling pathway in human myometrial and leiomyoma cell function. J Clin Endocrinol Metab. 2014;99:E775-E785.Islam M.S., Catherino W.H., Protic O., et al. Role of activin-A and myostatin and their signaling pathway in human myometrial and leiomyoma cell function. J Clin Endocrinol Metab. 2014;99:E775-E785.Moravek M.B., Yin P., Ono M., et al. Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications. Hum Reprod Update. 2015;21:1-12.Moravek M.B., Yin P., Ono M., et al. Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications. Hum Reprod Update. 2015;21:1-12.Reis F.M., Bloise E., Ortiga-Carvalho T.M. Hormones and pathogenesis of uterine fibroids. Best Practice & Research Clinical Obstetrics and Gynaecology. 2015;1-12.Reis F.M., Bloise E., Ortiga-Carvalho T.M. Hormones and pathogenesis of uterine fibroids. Best Practice & Research Clinical Obstetrics and Gynaecology. 2015;1-12.O’Connor K.A., Ferrell R., Brindle E., et al. Progesterone and ovulation across stages of the transition to menopause. Menopause. 2009;16:1178-1187.O’Connor K.A., Ferrell R., Brindle E., et al. Progesterone and ovulation across stages of the transition to menopause. Menopause. 2009;16:1178-1187.Bulun S.E., Moravek M.B., Yin P. et al. Uterine leiomyoma stem cells: linking progesterone to growth. Semin Reprod Med. 2015;33:357-365.Bulun S.E., Moravek M.B., Yin P. et al. Uterine leiomyoma stem cells: linking progesterone to growth. Semin Reprod Med. 2015;33:357-365.Grings A.O., Lora V., Ferreira G.D., et al. Protein expression of estrogen receptors alpha and beta and aromatase in myometrium and uterine leiomyoma. Gynecol Obstet Invest. 2012;73:113-117.Grings A.O., Lora V., Ferreira G.D., et al. Protein expression of estrogen receptors alpha and beta and aromatase in myometrium and uterine leiomyoma. Gynecol Obstet Invest. 2012;73:113-117.Tsigkou A., Reis F.M., Lee M.H., et al. Increased progesterone receptor expression in uterine leiomyoma: correlation with age, number of leiomyomas, and clinical symptoms. Fertil Steril. 2015;104:170-175.e171.Tsigkou A., Reis F.M., Lee M.H., et al. Increased progesterone receptor expression in uterine leiomyoma: correlation with age, number of leiomyomas, and clinical symptoms. Fertil Steril. 2015;104:170-175.e171.Ciavattini A., Di Giuseppe J., Stortoni P., et al. Uterine fibroids: pathogenesis and interactions with endometrium and endomyometrial junction. Obstet Gynecol Int. 2013;2013:173-184.Ciavattini A., Di Giuseppe J., Stortoni P., et al. Uterine fibroids: pathogenesis and interactions with endometrium and endomyometrial junction. Obstet Gynecol Int. 2013;2013:173-184.Luo N., Guan Q., Zheng L., et al. Estrogenmediated activation of fibroblasts and its effects on the fibroid cell proliferation. Transl Res. 2014;163:232-241.Luo N., Guan Q., Zheng L., et al. Estrogenmediated activation of fibroblasts and its effects on the fibroid cell proliferation. Transl Res. 2014;163:232-241.Kim J.J., Sefton E.C. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol Cell Endocrinol. 2012;358:223-231.Kim J.J., Sefton E.C. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol Cell Endocrinol. 2012;358:223-231.Осиновская Н.С., Иващенко Т.Э., Долинский А.К., Султанов И.Ю., Гимбовская С., ХоффманЭ., Беженарь В.Ф., Баранов В.С. Мутации гена MED12 у женщин с миомой матки. Генетика. 2013;49(12):1426-1431. [Osinovskaya N.S., Ivashchenko T.E., Dolinsky A.K., Sultanov I.Yu., Gimbovskaya S., Hoffman E., Bezhenar V.F., Baranov V.S. MED12 gene mutations in women with uterine myoma. Genetika. 2013;49(12):1426-1431] (In Russ).Осиновская Н.С., Иващенко Т.Э., Долинский А.К., Султанов И.Ю., Гимбовская С., ХоффманЭ., Беженарь В.Ф., Баранов В.С. Мутации гена MED12 у женщин с миомой матки. Генетика. 2013;49(12):1426-1431. [Osinovskaya N.S., Ivashchenko T.E., Dolinsky A.K., Sultanov I.Yu., Gimbovskaya S., Hoffman E., Bezhenar V.F., Baranov V.S. MED12 gene mutations in women with uterine myoma. Genetika. 2013;49(12):1426-1431] (In Russ).Liu S., Yin P., Kujawa S.A., Coon J.S. V, Okeigwe I., Bulun S.E. Progesterone receptor integrates the effects of mutated MED12 and altered DNA methylation to stimulate RANKL expression and stem cell proliferation in uterine leiomyoma. Oncogene. 2018 Dec 11. doi: 10.1038/s41388-018-0612-6.Liu S., Yin P., Kujawa S.A., Coon J.S. V, Okeigwe I., Bulun S.E. Progesterone receptor integrates the effects of mutated MED12 and altered DNA methylation to stimulate RANKL expression and stem cell proliferation in uterine leiomyoma. Oncogene. 2018 Dec 11. doi: 10.1038/s41388-018-0612-6.Адамян Л.В., Сонова М.М., Шамугия Н.М. Опыт применения селективных модуляторов рецеп- торов прогестерона в лечении миомы матки (обзор литературы). Проблемы репродукции. 2014;(4): 34-38 [Adamyan L.V., Sonova M.M., Shamugia N.M. Experience of using selective progesterone receptor modulators in the treatment of uterine fibroids (literature review). Problemy Reproduktsii. 2014;(4):34-38] (In Russ).Адамян Л.В., Сонова М.М., Шамугия Н.М. Опыт применения селективных модуляторов рецеп- торов прогестерона в лечении миомы матки (обзор литературы). Проблемы репродукции. 2014;(4): 34-38 [Adamyan L.V., Sonova M.M., Shamugia N.M. Experience of using selective progesterone receptor modulators in the treatment of uterine fibroids (literature review). Problemy Reproduktsii. 2014;(4):34-38] (In Russ).Шамугия Н.М., Адамян Л.В., Сонова М.М. и др. Новое в лечении миомы матки. Российский вестник акушера-гинеколога. 2015;3:76-80. [Shamugia N.M., Adamyan L.V., Sonova M.M, et al. New achievements in the treatment of uterine fibroids. Rossiyskiy Vestnik Akushera-Ginekologa. 2015;3:76-80.] (In Russ).Шамугия Н.М., Адамян Л.В., Сонова М.М. и др. Новое в лечении миомы матки. Российский вестник акушера-гинеколога. 2015;3:76-80. [Shamugia N.M., Adamyan L.V., Sonova M.M, et al. New achievements in the treatment of uterine fibroids. Rossiyskiy Vestnik Akushera-Ginekologa. 2015;3:76-80.] (In Russ).Адамян Л.В., Зайратьянц О.В., Тихомиров А.Л. и др. Антипролиферативное и проапоптоти- ческое действие селективного модулятора рецепторов прогестерона улипристала на лейомиому матки in vivo. Пробл. репродукции. 2014;3:25-28. [Adamyan L.V., Zaratyants O.V., Tikhomirov A.L., et al. The antiproliferative and proapoptotic effect of the selective progesterone receptor modulator ulipristal on uterine leiomyoma in vivo. Probl. Reproduktsii. 2014;3:25-28.] (In Russ).Адамян Л.В., Зайратьянц О.В., Тихомиров А.Л. и др. Антипролиферативное и проапоптоти- ческое действие селективного модулятора рецепторов прогестерона улипристала на лейомиому матки in vivo. Пробл. репродукции. 2014;3:25-28. [Adamyan L.V., Zaratyants O.V., Tikhomirov A.L., et al. The antiproliferative and proapoptotic effect of the selective progesterone receptor modulator ulipristal on uterine leiomyoma in vivo. Probl. Reproduktsii. 2014;3:25-28.] (In Russ).Тихомиров А.Л., Казенашев В.В. Улипристал ацетат – новые возможности в лечении лей- омиомы матки. Акуш. и гин. 2013;9:97-100. [Tikhomirov A.L., Kazenashev V.V. Ulipristal acetate: new opportunities in the treatment of uterine leiomyoma. Akush i Gin. 2013;9:97-100.] (In Russ).Тихомиров А.Л., Казенашев В.В. Улипристал ацетат – новые возможности в лечении лей- омиомы матки. Акуш. и гин. 2013;9:97-100. [Tikhomirov A.L., Kazenashev V.V. Ulipristal acetate: new opportunities in the treatment of uterine leiomyoma. Akush i Gin. 2013;9:97-100.] (In Russ).Тихомиров А.Л. Миома, патогенетическое обоснование органосохраняющего лече- ния. Монография. М., 2013. [Tikhomirov A.L. Myoma, pathogenetic rationale for organ preservation treatment. Monograph. M., 2013.] (In Russ).Тихомиров А.Л. Миома, патогенетическое обоснование органосохраняющего лече- ния. Монография. М., 2013. [Tikhomirov A.L. Myoma, pathogenetic rationale for organ preservation treatment. Monograph. M., 2013.] (In Russ).Malik M., Britten J., Cox J., et al. Gonadotropinreleasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones. Fertil Steril. 2015. 10.1016/j. fertnstert.2015.09.006 [Published online Sep 26, 2015.].Malik M., Britten J., Cox J., et al. Gonadotropinreleasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones. Fertil Steril. 2015. 10.1016/j. fertnstert.2015.09.006 [Published online Sep 26, 2015.].Chung Y.J., Chae B., Kwak S.H., et al. Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro. Int J Med Sci. 2014;11:276-281.Chung Y.J., Chae B., Kwak S.H., et al. Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro. Int J Med Sci. 2014;11:276-281.Карева Е.Н. Мифепристон и миома матки. Фарматека. 2010;14:18-30. [Kareva E.N. Mifepristone and uterine fibroids. Pharmateca. 2010;14:18-30.] (In Russ).Карева Е.Н. Мифепристон и миома матки. Фарматека. 2010;14:18-30. [Kareva E.N. Mifepristone and uterine fibroids. Pharmateca. 2010;14:18-30.] (In Russ).Chabbert-Buffet N., Esber N., Bouchard P. Fibroid growth and medical options for treatment. Fertil Steril. 2014;102:630-639.Chabbert-Buffet N., Esber N., Bouchard P. Fibroid growth and medical options for treatment. Fertil Steril. 2014;102:630-639.Römer T. Long-term intermittent treatment with ulipristal acetate avoids hysterectomy (Langzeitintervalltherapie mit Ulipristalacetat vermeidet Hysterektomie). Der Privatarzt Gynäkologie. 2016;7(22-23). doi: 10.1007/s41975-017-0002-4.Römer T. Long-term intermittent treatment with ulipristal acetate avoids hysterectomy (Langzeitintervalltherapie mit Ulipristalacetat vermeidet Hysterektomie). Der Privatarzt Gynäkologie. 2016;7(22-23). doi: 10.1007/s41975-017-0002-4.Ono M., Qiang W., Serna V.A., et al. Role of stem cells in human uterine leiomyoma growth. PLoS One. 2012;7:e36935.Ono M., Qiang W., Serna V.A., et al. Role of stem cells in human uterine leiomyoma growth. PLoS One. 2012;7:e36935.Morikawa А., Ohara N., Xu Q., et al. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. Hum Reprod. 2008;23:944-951.Morikawa А., Ohara N., Xu Q., et al. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. Hum Reprod. 2008;23:944-951.Fischl F. Ulipristal acetate (UPA) as conservative fibroid treatment and bleeding control in uterus myomatosis (Ulipristalacetat (UPA) zur konservativen Myomtherapie und Blutungskontrolle bei Uterus myomatosus) Journal für Gynäkologische Endokrinologie. 2016;10(1):30–36.Fischl F. Ulipristal acetate (UPA) as conservative fibroid treatment and bleeding control in uterus myomatosis (Ulipristalacetat (UPA) zur konservativen Myomtherapie und Blutungskontrolle bei Uterus myomatosus) Journal für Gynäkologische Endokrinologie. 2016;10(1):30–36.Pharmacovigilance Risk Assessment Committee (PRAC) has initiated a review of Esmyahttp://www.richter.hu/en-S/investors/announcements/Pages/extraord171204b.aspx.Pharmacovigilance Risk Assessment Committee (PRAC) has initiated a review of Esmyahttp://www.richter.hu/en-S/investors/announcements/Pages/extraord171204b.aspx.http://www.roszdravnadzor.ru/i/upload/images/2018/4/11/1523459448.3577-1-21581.pdf.http://www.roszdravnadzor.ru/i/upload/images/2018/4/11/1523459448.3577-1-21581.pdf.Donnez J., Courtoy G.E. & Dolmans M.-M. Fibroid management in premenopausal women. Climacteric. doi: 10.1080/13697137.2018.1549216.Donnez J., Courtoy G.E. & Dolmans M.-M. Fibroid management in premenopausal women. Climacteric. doi: 10.1080/13697137.2018.1549216.Donnez J., Courtoy G.E., Donnez O., Dolmans M.M. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review. Reprod Biomed Online. 2018;37:216–23.Donnez J., Courtoy G.E., Donnez O., Dolmans M.M. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review. Reprod Biomed Online. 2018;37:216–23.Donnez J. Liver injury and ulipristal acetate: an overstated tragedy? Fertil Steril. 2018;110:593–5.Donnez J. Liver injury and ulipristal acetate: an overstated tragedy? Fertil Steril. 2018;110:593–5.Donnez J., Tatarchuk T.T., Bouchard P. et al. for the PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N. Engl. J. Med. 2012;366:409-420.Donnez J., Tatarchuk T.T., Bouchard P. et al. for the PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N. Engl. J. Med. 2012;366:409-420.Donnez J., Tomaszewski J., Vazquez F. et al. for the PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N. Engl. J. Med. 2012;366:421-432.Donnez J., Tomaszewski J., Vazquez F. et al. for the PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N. Engl. J. Med. 2012;366:421-432.Donnez J., Tomaszewski J., Vazquez F. et al., for the PEARL III Study Group. Long term treatment. Gynecology and Menopause. 2014:9-18.Donnez J., Tomaszewski J., Vazquez F. et al., for the PEARL III Study Group. Long term treatment. Gynecology and Menopause. 2014:9-18.Donnez J., Hudecek R., Donnez O. et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril. 2015;103:519-527.e513.Donnez J., Hudecek R., Donnez O. et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril. 2015;103:519-527.e513.Donnez J., et al. PEARL IV PART 2. Fertil Steril. 2016;105(1):165-173.Donnez J., et al. PEARL IV PART 2. Fertil Steril. 2016;105(1):165-173.Fauser B.C.J.M., Donnez J., Bouchard Ph., Barlow D.H., Vázquez F., Arriagada P., Skouby S.O., Palacios S., Tomaszewski Ja., Lemieszczuk B., William A.R.W. Safety after extended repeated use of ulipristal acetate for uterine fibroids. PLoS One. 2017 Mar 7;12(3):e0173523. doi: 10.1371/journal.pone.0173523.Fauser B.C.J.M., Donnez J., Bouchard Ph., Barlow D.H., Vázquez F., Arriagada P., Skouby S.O., Palacios S., Tomaszewski Ja., Lemieszczuk B., William A.R.W. Safety after extended repeated use of ulipristal acetate for uterine fibroids. PLoS One. 2017 Mar 7;12(3):e0173523. doi: 10.1371/journal.pone.0173523.

The authors declare that there are no conflicts of interest present.